⌕
VIR Biotechnology · VIR · Nasdaq
Tenet 54 · Mixed
Compare
$9.25−3.44%At closeTenet 54 · Mixed
$9.25−0.33 (−3.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

VIR Biotechnology (VIR) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

38 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 96% below its peak, net margin −638.9%.
The four lines that matter · FY21–FY25
Revenue ($M)▼7.6%
68.6
FY21→FY25CAGR −50.0%/yr
Net income ($M)▲16.1%
−438.0
one-off year: see footnoteCAGR —
Free cash flow ($M)▲12.6%
−396.6
FY21→FY25CAGR —
Diluted EPS▲17.5%
−3.16
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+3.8%

133.4mn → 138.5mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$4.8M

−33.8% YoY in FY25 · 7.0% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)68556.0Revenue−26.0COGS−455966.0R&D−92074.0SG&A−479328.0Op income41341.0Tax & other−437987.0Net income

-639¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -638.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
302,828.068,556.074,205.086,180.01,615,797.01,095,415.0▼7.6%−50.0%
Cost of revenue
15.026.0845.02,765.0146,319.065,865.0▼96.9%−85.9%
Gross profit
302,813.0—A73,360.083,415.01,469,478.01,029,550.0——
Research & development
412,594.0455,966.0506,499.0579,720.0474,648.0448,006.0▼10.0%+0.4%
Selling, general & admin
101,581.092,074.0119,031.0174,441.0161,762.0160,793.0▼22.6%−13.0%
Total operating expenses
514,186.0547,858.0660,525.0767,720.0636,410.0608,799.0▼17.1%−2.6%
Operating incomefeeds ROC rank
−211,402.0−479,328.0−587,165.0−684,305.0833,068.0420,751.0▲18.4%—
Other income, net
26,681.041,558.064,060.056,111.0−78,788.0129,051.0——
Pretax income
−184,721.0−437,770.0−523,105.0−628,194.0754,280.0549,802.0▲16.3%—
Income tax
69.0217.0−1,145.0−13,077.0238,443.021,218.0—−68.2%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−184,790.0−437,987.0−521,960.0−615,061.0515,837.0528,584.0▲16.1%—
Per share
Diluted EPSbuyback-sensitive
−1.26−3.16−3.83−4.593.833.96▲17.5%—
Diluted shares (mn)
169.28138.52136.25134.13134.81133.44▲1.7%+0.9%
Margins
Gross margin100th pct in Healthcare
100.0%—A98.9%96.8%90.9%94.0%——
Operating margin
−69.8%−699.2%−791.3%−794.0%51.6%38.4%▲92.1pp−737.6pp
Net margin13th pct in Healthcare
−61.0%−638.9%−703.4%−713.7%31.9%48.3%▲64.5pp−687.1pp
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 32% vs a 2% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
FY17 – FY20 · 4 more years
Unlock the full history →
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-23 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was VIR Biotechnology's revenue last fiscal year?

VIR Biotechnology reported revenue of $68.6M in fiscal 2025, down 7.6% from fiscal 2024.

What was VIR Biotechnology's net income?

VIR Biotechnology reported net income of −$438.0M in fiscal 2025, a net margin of −638.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.